Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Immunogenicity, and Efficacy of a Chlamydia Trachomatis mRNA Vaccine Candidate in Adults Aged 18 to 29 Years
Conditions
Interventions
Chlamydia mRNA Vaccine
Placebo
Locations
7
Australia
Investigational Site Number : 0360002
Bruce, Australian Capital Territory, Australia
Investigational Site Number : 0360006
Maroubra, New South Wales, Australia
Investigational Site Number : 0360005
Sydney, New South Wales, Australia
Investigational Site Number : 0360001
Albion, Queensland, Australia
Investigational Site Number : 0360004
Morayfield, Queensland, Australia
Investigational Site Number : 0360003
Southport, Queensland, Australia
Start Date
March 27, 2025
Primary Completion Date
January 3, 2028
Completion Date
January 3, 2028
Last Updated
April 8, 2026
Trial Transparency email recommended (Toll free for US & Canada)
CONTACT
800-633-1610Contact-US@sanofi.comLead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions